Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.

Wong SY, Lee ARYB, Sia AHJ, Wo YJ, Teo YH, Teo YN, Syn NL, Ong CC, Teo LL, Yeo TC, Poh KK, Kong WK, Wong RC, Sia CH

Cardiovascular drugs and therapy12 Jul 2022Cited by 19 (Europe PMC)

PMID35819544DOI10.1007/s10557-022-07360-wPepBankPUB-35819544

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

2 results from studies that gave the peptide. 2 results from people.

01HumanSystematic reviewEfficacy outcome
In the pooled trials, liraglutide, but not exenatide, improved systolic function by increasing left ventricular ejection fraction versus placebo.
In plain wordsIn the pooled trials, liraglutide improved how strongly the heart pumps compared with placebo.
Peptide
Liraglutide
Outcome
IncreaseLeft ventricular ejection fraction with liraglutide
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
mean difference
4.89
left ventricular ejection fraction
Source sentences
Summary
Liraglutide, but not exenatide, demonstrated improved systolic function, by increasing left ventricular ejection fraction (MD= 4.89; 95% CI: 3.62 to 6.16; P< 0.00001
1 context sentence(design, population, supporting numbers)
Summary · context
20 reports of 19 randomized placebo-controlled trials including 2062 participants were meta-analyzed.
Report a problemFND-3581954404
02HumanSystematic reviewEfficacy outcome
In the pooled trials, liraglutide reduced left ventricular end-systolic volume versus placebo.
In plain wordsIn the pooled trials, liraglutide reduced the amount of blood left in the heart after each beat compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseLeft ventricular end-systolic volume with liraglutide
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
mean difference
−4.15
left ventricular end-systolic volume
Source sentences
Summary
and reducing left ventricular end-systolic volume (MD= -4.15; 95% CI: -7.49 to -0.81; P = 0.01; I²= 0%).
1 context sentence(design, population, supporting numbers)
Summary · context
20 reports of 19 randomized placebo-controlled trials including 2062 participants were meta-analyzed.
Report a problemFND-3581954405

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1RAs improved systolic function measured by circumferential strain versus placebo.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group improved a measure of heart pumping compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseSystolic function (circumferential strain) in type 2 diabetes
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Measurements
mean difference
−5.48
circumferential strain
Source sentences
Summary
GLP-1RA resulted in improved systolic function measured by circumferential strain (mean difference [MD]= -5.48; 95% CI: -10.47 to -0.49; P= 0.03; I²= 89%)
1 context sentence(design, population, supporting numbers)
Summary · context
20 reports of 19 randomized placebo-controlled trials including 2062 participants were meta-analyzed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3581954401
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1RAs improved diastolic dysfunction measured by E/A versus placebo.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group improved a measure of heart relaxation compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseDiastolic function (E/A) in type 2 diabetes
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Measurements
mean difference
−0.15
E/A
Source sentences
Summary
and diastolic dysfunction measured by E / A (MD= -0.15; 95% CI: -0.25 to -0.05; P= 0.003; I²= 0%).
1 context sentence(design, population, supporting numbers)
Summary · context
20 reports of 19 randomized placebo-controlled trials including 2062 participants were meta-analyzed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3581954402
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients after myocardial infarction, pooled GLP-1RAs reduced infarct size versus placebo.
In plain wordsIn people after a heart attack, GLP-1 drugs as a group reduced the size of the damaged heart area compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseInfarct size after myocardial infarction
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Measurements
mean difference
−5.36 g
infarct size
Source sentences
Summary
For post-myocardial infarction patients, GLP-1RA reduced infarct size (g) (MD= -5.36; 95% CI: -10.68 to -0.04; P= 0.05; I²= 78%).
1 context sentence(design, population, supporting numbers)
Summary · context
20 reports of 19 randomized placebo-controlled trials including 2062 participants were meta-analyzed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3581954403
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with heart failure, pooled GLP-1RAs gave no significant change in cardiac function versus placebo.
In plain wordsIn people with heart failure, GLP-1 drugs as a group made no significant change to heart function compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeCardiac function in heart failure
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
Among heart failure patients, no significant changes were noted.
1 context sentence(design, population, supporting numbers)
Summary · context
20 reports of 19 randomized placebo-controlled trials including 2062 participants were meta-analyzed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3581954406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.